Clinical trials: HIV Infections, completed
Cervical Cancer, Human Papillomavirus Infection
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is…
- Conditions
- Cervical Cancer, Human Papillomavirus Infection, Human Immunodeficiency Virus, Cervical Dysplasia
- Trial name
- NCT06915779
- Where
- 13 sites in Canada
- Volunteers
- 241 people
- Sponsor
- University of British Columbia
HIV Infections
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
This study will determine whether HIV treatment that is initiated during the acute phase of HIV infection, followed by discontinuation of treatment, is effective in reducing the amount of HIV and an increasing the amount of CD4…
- Trial name
- NCT00705926
- Testing
- Highly Active Antiretroviral Therapy (HAART), No treatment
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
HIV, Pharmacokinetics
TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.
TMC125 is from the class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). NNRTIs work by blocking reverse transcriptase, a protein that HIV needs to make more copies of itself.
- Trial name
- NCT00828815
- Testing
- TMC125
- Volunteers
- 22 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV, Contraception
Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women
The purpose of this study is to determine the acceptability of randomization to contraceptive options and estimate the effect of progestin contraception on HIV genital shedding and inflammatory/immune perturbations in women who…
- Trial name
- NCT02103660
- Testing
- Depo-Medroxyprogesterone Acetate, Progestin Contraceptive (Jadelle)
- Where
- Malawi
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised
The purpose of this study is to determine the role of HIV-specific CD4 T cell responses and immune responses dependent upon these CD4 responses that develop when antiretroviral drugs are started during acute or recent HIV…
- Trial name
- NCT00238459
- Testing
- Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized
- Where
- 2 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, STIs
The South-East Asian Transgender Health Cohort
This is a prospective observational cohort study that will enroll 300 HIV-negative transgender people and 150 transgender people living with HIV from 4 community health centers in Thailand, Vietnam, and the Philippines.
- Conditions
- HIV, STIs, HCV
- Trial name
- SEATrans (NCT05454579)
- Where
- 5 sites in Philippines, Thailand and 1 more
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Institute of HIV Research and Innovation Foundation, Thailand
Coronary Heart Disease, HIV Infection
Prognosis of Acute Coronary Syndrome in HIV-infected Patients
Objectives: Evaluate differences for mortality, morbidity and the cardiovascular risk factors between HIV and non-HIV patients with an acute coronary syndromes (ACS) after a 3-years follow up.
- Trial name
- NCT00139958
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Saint Antoine University Hospital
HIV Infections
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
To demonstrate that the antiviral activity and safety/tolerability of a test regimen of indinavir is equivalent to that of a control regimen of indinavir when each is coadministered with zidovudine (ZDV) (or stavudine, d4T) and…
- Trial name
- NCT00002208
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 15 sites in United States
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection, Coronary Heart Disease
High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV
HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily) in HIV-infected persons taking…
- Trial name
- HILLCLIMBER (NCT02841774)
- Testing
- Pravastatin, Rosuvastatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew Feinstein
HIV/AIDS
The Prevention Options for Women Evaluation Research (POWER) Cohort
The POWER Cohort study is a PrEP implementation project to demonstrate Pre-exposure prophylaxis (PrEP) delivery for young women in Cape Town and Johannesburg, South Africa and Kisumu, Kenya.
- Trial name
- NCT03490058
- Testing
- Truvada
- Where
- 3 sites in Kenya, South Africa
- Volunteers
- 2,255 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections, Hepatitis C
Prevalence of Hepatitis C Virus Infection in HIV-Infected Children
The purpose of this study is to find out how many children who are infected with HIV are also infected with hepatitis C virus (HCV). HCV infection is a major health concern.
- Trial name
- NCT00037076
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HCV Infections
Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
The objective of this study is to evaluate the effect of boceprevir (steady state) on the pharmacokinetics of a single dose of raltegravir.
- Trial name
- OPAL (NCT01288417)
- Testing
- boceprevir, raltegravir
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
HIV Infection, Hepatitis C
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/ HCV (hepatitis C virus) coinfected persons…
- Trial name
- NCT01285050
- Testing
- Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
HIV Infections
Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence
This research study uses a cluster randomized controlled trial design to evaluate the effectiveness of Treatment Text (TXTXT) intervention on adherence and viral load suppression at 3- and 6- months post intervention initiation…
- Trial name
- NCT05783297
- Testing
- Treatment Text (TXTXT), Standard of Care
- Where
- 12 sites in United States
- Volunteers
- 210 people
- Sponsor
- Amy K. Johnson, PhD, MSW
Sarcoma, Kaposi, HIV Infections
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha.
- Trial name
- NCT00001113
- Testing
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cryptosporidiosis, HIV Infections
A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS
To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo…
- Trial name
- NCT00002278
- Testing
- Diclazuril
- Where
- 3 sites in United States
- Sponsor
- Janssen, LP
HIV, Cardiovascular Diseases
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART).
- Trial name
- REPRIEVE (NCT02344290)
- Testing
- Pitavastatin
- Where
- 137 sites in United States, Botswana and 11 more
- Volunteers
- 7,769 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Disease, Bipolar Disorder
Texting to Improve Adherence in HIV+ With Bipolar Disorder
Adherence to combination antiretroviral therapy (ART) is critical for successful HIV viral suppression. Nonadherence to ART poses several potentially serious health consequences, including higher viral loads, faster progression…
- Trial name
- iTAB (NCT02090634)
- Testing
- Psychoeducation, individualized Texting for Adherence Building (iTAB)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of California, San Diego
HIV/AIDS
Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy
The purpose of this study is to evaluate cumulative exposure to tenofovir diphosphate (TFV-DP) using dried blood spots (DBS) in treated HIV-infected patients who are receiving a TFV-based regimen.
- Trial name
- 2104 (NCT02012621)
- Where
- United States
- Volunteers
- 807 people
- Sponsor
- University of Colorado, Denver
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
To extend the evaluation of safety and immunogenicity of MN recombinant soluble gp120/HIV-1 (MN rsgp120/HIV-1) in combination with QS21 with or without alum and on two different vaccination schedules.
- Trial name
- NCT00001052
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 5 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.